Newsroom November 13, 2024 Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership to Advance Affinia Therapeutics’ Pipeline of Next-Generation Gene Therapies to the Clinic View More October 22, 2024 Affinia Therapeutics to Highlight New Data on Genetic Cardiomyopathy Programs and BBB-Penetrant Capsids Leveraging Novel Receptors at the European Society of Gene & Cell Therapy 2024 31st Annual Congress View More September 24, 2024 Affinia Therapeutics to Participate in Upcoming Investor and Industry Conferences View More September 10, 2024 Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer View More May 28, 2024 Affinia Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference View More May 10, 2024 Affinia Therapeutics Presents Preclinical Data for Genetic Cardiomyopathy and Sporadic ALS Programs with Novel Cardiotropic and BBB-Penetrant AAV Capsids at the American Society of Gene & Cell Therapy 2024 Annual Meeting View More
